Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
Cassava Sciences Shares Plunge on Indictment Against Former Advisor -- Barrons.com
Needham Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $294
Express News | Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Biogen, Eisai Launch Leqembi in China to Treat Alzheimer's Disease
Eisai and Biogen Launch Alzheimer's Drug Leqembi in China
Express News | 'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
Forecasting The Future: 19 Analyst Projections For Biogen
Is Biogen Stock Underperforming the Nasdaq?
Biogen Analyst Ratings
RBC Capital Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $317
Express News | 'Biogen Has Up To $10B For Its Next M&A Bets' - Bloomberg News
Biogen Inc. (BIIB) Is a Top-Ranked Momentum Stock: Should You Buy?
Express News | Tofidence™ (Tocilizumab), a Biosimilar Referencing Roactemra®, Approved in the European Union
Wells Fargo Maintains Biogen(BIIB.US) With Hold Rating, Maintains Target Price $240
Biogen to Report Second Quarter 2024 Financial Results August 1, 2024
Add Portfolio Diversity With These BMO Value Stock Picks
Investors Three-year Losses Continue as Biogen (NASDAQ:BIIB) Dips a Further 3.3% This Week, Earnings Continue to Decline
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug